The leading name in the healthcare business, Eli Lilly and Co (NYSE:LLY), has decided to approach BioNTech to form the most sought after collaboration on cancer immunotherapy. As per the reports, the company will hand over $30 million for the equity and $30 million as the signing bonus to BioNTech. It has also promised to offer up to $300 million for each time any agreed upon milestone is achieved.
Why BioNTech:
If taken into consideration all the newly formed biotech companies in the European region, one need not think twice before calling BioNTech as one of the fastest growing start-ups there. It employs over 300 people and is backed by billionaire brothers Thomas and Andreas. Due to all these facts, the company manages to find itself at the top of the list whenever someone decides to head to the European biotech market.
One of the subsidiary companies named Cell & Gene Therapies has been working hard on the engineering of chimeric antigen receptors and T cell receptors. These receptors are capable of putting a direct immune assault on a few cancers. BioNTech had put the Adapt immune of U.K. into the limelight with a lucrative Initial Public Offering. Other companies that are giving a stiff competition to BioNTech include Kite and Juno Therapeutic.
Most of the sector leaders have been hit hard by toxicity issues like cytokine storms that can easily threaten any patient. The fact that has helped BioNTech earned fame lately is nothing but its work on TCR cloning that has been taken from samples of the patients. The process doesn’t take more than 11 days, which is a lot faster than the other procedures available in the market.
The senior management of Eli Lilly and Co (NYSE:LLY) hopes that this agreement with BioNTech will help it sort out some of the most important issues in the medical science and come up with appropriate solutions shortly.
